777 related articles for article (PubMed ID: 25518048)
1. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
3. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
[TBL] [Abstract][Full Text] [Related]
4. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
5. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
[TBL] [Abstract][Full Text] [Related]
6. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.
Patel A; Panchal H; Dubinsky MC
Inflamm Bowel Dis; 2017 Sep; 23(9):1600-1604. PubMed ID: 28590341
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin testing can identify ineffective colorectal cancer surveillance procedures in patients with longstanding colitis.
Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
Inflamm Bowel Dis; 2014 Jun; 20(6):1079-84. PubMed ID: 24788218
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
[TBL] [Abstract][Full Text] [Related]
10. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
11. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases.
Diamanti A; Colistro F; Basso MS; Papadatou B; Francalanci P; Bracci F; Muraca M; Knafelz D; De Angelis P; Castro M
Inflamm Bowel Dis; 2008 Sep; 14(9):1229-35. PubMed ID: 18398894
[TBL] [Abstract][Full Text] [Related]
12. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
13. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
14. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
15. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease.
Bunn SK; Bisset WM; Main MJ; Gray ES; Olson S; Golden BE
J Pediatr Gastroenterol Nutr; 2001 Jul; 33(1):14-22. PubMed ID: 11479402
[TBL] [Abstract][Full Text] [Related]
18. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
J Clin Gastroenterol; 2018 Aug; 52(7):e53-e62. PubMed ID: 28723856
[TBL] [Abstract][Full Text] [Related]
19. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission.
Kawashima K; Oshima N; Kishimoto K; Kataoka M; Fukunaga M; Kotani S; Sonoyama H; Oka A; Mishima Y; Kazumori H; Ishikawa N; Araki A; Ishihara S
Inflamm Bowel Dis; 2023 Mar; 29(3):359-366. PubMed ID: 35583193
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
